Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer drugs
Biotech
AbbVie halts development of Dragonfly cancer asset in midflight
AbbVie has terminated a phase 1 trial of the natural killer-cell engager ABBV-303, licensed from Dragonfly as part of an ongoing partnership.
Darren Incorvaia
Oct 29, 2025 1:47pm
Lilly oncology head weighs in on FDA cancer drug policies
Oct 21, 2025 11:53am
Vivace hits high note in midstage mesothelioma trial
Oct 19, 2025 10:30am
French antibody biotech draws in $122M for push to clinic
Oct 16, 2025 11:19am
Tubulis touts $361M series C as next-gen ADC data drop nears
Oct 15, 2025 5:01am
Australian biotech partners with Pi Health for cancer trial
Sep 4, 2025 8:30am
